SIO Integrative Program
Opens Nov 3 2021 12:00 AM (CDT)
Deadline Feb 1 2022 11:59 PM (CST)
Description

Gateway is focused on funding integrative oncology research that pairs conventional therapies with evidence-based integrative therapies to manage symptoms and side effects from treatment. This also aims to increase quality of life, especially post-treatment. Grants are generally awarded for a 2-5 year period, with total award amounts generally ranging from $200,000 to $1.5 million.

The application process has a rolling Letter of Intent (LOI) submission which is aggregated four times a year. 

  • LOI submission – As part of a Letter of Intent (LOI), researchers answer basic questions about fit with Gateway’s mission and funding criteria, and provide contact information, high level information related to the proposed project, a concise summary of the study rationale, current standard of care, an overview of specific aims/objectives, and proposed research design/approach. LOIs are pre-generated/templated applications and must be submitted before the deadline listed on our GMS to be reviewed in upcoming cycle.
  • LOI review – LOIs are assigned to scientists on Gateway’s Research and Grants Committee for peer review. The LOIs are reviewed within seven days after the LOI deadline has passed. 
  • Full Grant invitation to submit – Applicants who demonstrate that their project is in line with Gateway’s mission and are approved by the peer reviewers are invited to submit a Full Grant Application (FGA). Applicants will be given 4-5 weeks to complete a full grant application.
  • Full Grant review – Once the full grant application is submitted to Gateway, each application is reviewed by the full Research and Grants Committee at a convened meeting and given a score per the NIH scoring model to indicate funding priority. The most promising grants are presented to Gateway’s Board of Directors.
  • Full Grant approval – Gateway’s Board of Directors reviews the promising grants and determines final fiduciary approval of grant awards. 

 

Apply

SIO Integrative Program


Gateway is focused on funding integrative oncology research that pairs conventional therapies with evidence-based integrative therapies to manage symptoms and side effects from treatment. This also aims to increase quality of life, especially post-treatment. Grants are generally awarded for a 2-5 year period, with total award amounts generally ranging from $200,000 to $1.5 million.

The application process has a rolling Letter of Intent (LOI) submission which is aggregated four times a year. 

  • LOI submission – As part of a Letter of Intent (LOI), researchers answer basic questions about fit with Gateway’s mission and funding criteria, and provide contact information, high level information related to the proposed project, a concise summary of the study rationale, current standard of care, an overview of specific aims/objectives, and proposed research design/approach. LOIs are pre-generated/templated applications and must be submitted before the deadline listed on our GMS to be reviewed in upcoming cycle.
  • LOI review – LOIs are assigned to scientists on Gateway’s Research and Grants Committee for peer review. The LOIs are reviewed within seven days after the LOI deadline has passed. 
  • Full Grant invitation to submit – Applicants who demonstrate that their project is in line with Gateway’s mission and are approved by the peer reviewers are invited to submit a Full Grant Application (FGA). Applicants will be given 4-5 weeks to complete a full grant application.
  • Full Grant review – Once the full grant application is submitted to Gateway, each application is reviewed by the full Research and Grants Committee at a convened meeting and given a score per the NIH scoring model to indicate funding priority. The most promising grants are presented to Gateway’s Board of Directors.
  • Full Grant approval – Gateway’s Board of Directors reviews the promising grants and determines final fiduciary approval of grant awards. 

 

Apply
Opens
Nov 3 2021 12:00 AM (CDT)
Deadline
Feb 1 2022 11:59 PM (CST)